Interscience

What Interscience does

Interscience Co., Ltd. (株式会社インターサイエンス社) is a Japanese pharmaceutical communication agency founded in March 1988 as a spin-off of the promotion agency division from Medical Review Co., Ltd. Operating as a subsidiary of Medical Intelligence Holdings Inc. (MIHD), it provides integrated B2B services to pharmaceutical companies in Japan across seven core units: Account Service, Medical Writing, Creative, Digital Solution, Video/Studio, Strategic Planning, and Publication Support. Its named client base includes major domestic and multinational pharmaceutical companies such as Astellas, Takeda, Daiichi Sankyo, Chugai, Pfizer Japan, Novartis, AstraZeneca, Eli Lilly Japan, Mitsubishi Tanabe, and Bristol-Myers Squibb K.K., with project-based, medium-to-long-term engagements delivered through approximately 170 employees across Osaka and Tokyo headquarters.

The company's technology stack spans traditional medical communications (medical writing, creative design, academic publication support, Veeva CRM detailing apps, video production including 2D/3D CG and VR/AR) and two proprietary digital platforms: Medicil, a video-first disease information platform for rare and intractable diseases launched in October 2025, and JME (Japan Medical Evidence), a free LLM-based chat service for physicians launched in beta in July 2026 that draws on PubMed literature and a proprietary medical dictionary derived from clinical guidelines and Medical Review's published assets. The January 2026 acquisition of 51% of Vivixy Co., Ltd. by parent MIHD adds AI and web engineering capability to the group.

Revenue is generated primarily through professional services fees for project-based engagements; pricing is bespoke and not publicly disclosed. Go-to-market is direct enterprise field sales targeting pharmaceutical company marketing, medical affairs, and product launch teams. The company holds ISO/IEC 27001 (ISMS, 2025) and ISO 14001 (2022) certifications across both headquarters. Geographic operations are domestic Japan, with strategic partnerships (notably MedicalNote) extending reach into patient-facing channels.

Name

Interscience

Legal name

株式会社インターサイエンス社

Website

https://interscience.co.jp

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Marketing Services

NAICS

Advertising Agencies (541810), Advertising, Public Relations, and Related Services (5418)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Health Services (8000)

akta.pro primary industry

Healthcare/Pharma Creative Agencies (MPAAAAAJ)

akta.pro secondary industries

Medical Writing & Clinical Documentation FSP (HLAGAOAC), Medical Affairs Scientific Communications (MSL Support/Scientific Response) (HLAGALAF)

Keywords

• Pharmaceutical marketing services
• Medical communications agency
• Medical writing services
• Pharmaceutical advertising
• Healthcare content production

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Marketing Services: Project-based service fees for medical communication services including planning, creative development, medical writing, digital solutions, video production, and publication support for pharmaceutical companies. Services are tailored to specific client needs and typically involve medium to long-term engagements.
2. Publication Support Services: Fees for supporting academic paper writing, submission, peer review process, and post-publication support. Can include clinical research support, statistical analysis, and data interpretation services.
3. Video Content Production: Production fees for medical explanation videos, MOA animations, disease awareness videos, conference booth videos, and training materials using live action, 2D/3D CG, VR/AR, and generative AI technologies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Interscience is a B2B pharmaceutical communication agency that provides integrated marketing, medical writing, creative design, digital, video, strategic planning, and publication support services to pharmaceutical companies in Japan. Its seven service units — Account Service, Medical Writing, Creative, Digital Solution, Video/Studio, Strategic Planning, and Publication Support — flexibly combine to deliver compliant medical promotion, product launch support, disease awareness campaigns, HCP detailing tools, and academic publication assistance. Complementary platforms include the Medicil rare/intractable disease information site and the JME AI chat service for physicians.

Product overview

Interscience is a pharmaceutical communication agency providing integrated services across seven core units: Account Service (client partnership), Medical Writing (copywriting and editing), Creative (design and branding), Digital Solution (websites and apps), Video/Studio (video production), Strategic Planning, and Publication Support. These units flexibly combine to serve pharmaceutical clients' needs from product promotion to disease awareness. Key products include Medicil (rare disease information platform) and JME (AI-powered medical evidence chat for physicians). The company operates within the MIHD group alongside Medical Review, Medical Professional Relations, and Hearts companies.

Differentiator

Problem solved

Functional benefit

Brands

• Medicil (メディシル): A disease information website specializing in rare and intractable diseases, launched in October 2025. Provides video-based content to deliver reliable medical information in an easy-to-understand format.

Products and services

• Account Service (企画営業部) Client partnership and project management service handling schedule, budget, and staffing for pharmaceutical product promotion projects. Serves pharmaceutical companies requiring integrated medical marketing project delivery.
• Medical Writing (企画制作部) Medical copywriting, academic conference coverage, doctor interviews, editing, and promotional material planning for pharmaceutical products.
• Creative (クリエイティブ部) Design and branding services including key visuals, logos, promotional materials, and disease awareness tool creation.
• Digital Solution (デジタルソリューション部) Website production, treatment support apps, detailing applications (Veeva CRM), and omni-channel digital promotion planning for healthcare professionals and patients.
• Video/Studio (映像・スタジオ事業部) Video production services including doctor explanation videos, MOA animations, disease awareness content, and conference booth videos with 2D/3D CG and generative AI capabilities.
• Strategic Planning (企画戦略部) Communication strategy development and planning services for pharmaceutical marketing campaigns.
• Publication Support Service (パブリケーション・サポート・サービス) Full-service academic paper writing and submission support including manuscript creation, peer review coordination, and journal submission in Japanese and English.
• Medicil (メディシル) Rare disease and intractable disease information platform providing video-centered content for patient education and disease awareness.
• JME (Japan Medical Evidence) Free AI chat service for Japanese physicians providing evidence-based medical information using PubMed papers and proprietary medical dictionary.
• MedicalNote Partnership Services Patient-oriented disease awareness marketing support in partnership with MedicalNote Inc., leveraging their Medical Note platform with 3,100+ physicians.

Quantifiable outcome

• Worked with 1,064 medical facilities and 33 pharmaceutical/medical device companies on disease awareness
• +1 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability7 records

Feature2 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Vivixy Co., Ltd.coreTechnology or Integration · 26 January 2026MIHD acquired 51% of Vivixy's shares, making it a subsidiary. Vivixy brings AI technology and web technology expertise to the group. The acquisition aims to combine MIHD's business foundation with Vivixy's AI development capabilities for new AI-based business creation, AI utilization across the MIHD group, and digital transformation in healthcare settings.
• MedicalNote, Inc.coreStrategic or Co-development Partner · 14 November 2024Strategic partnership between MIHD group (including Interscience) and MedicalNote to strengthen disease awareness initiatives for patients. Combines MIHD's physician-centered marketing expertise with MedicalNote's patient journey-based marketing and Japan's largest patient medical information media platform (Medical Note). Aims to provide comprehensive marketing support to pharmaceutical companies addressing both physicians and patients.
• Medical Intelligence Holdings Inc. (MIHD)coreOthersParent company of Interscience. MIHD operates as a group with core business in advertising agency services specializing in prescription pharmaceuticals. Group companies include Medical Review Co., Ltd. (medical publishing), Medical Professional Relations Inc., and HEARTS, Inc.
• Medical Review Co., Ltd.coreOthersGroup company founded in 1983 as a medical book publisher. Provides accurate medical information and now focuses on marketing support for pharmaceutical clients. Creates medical publishing assets and provides healthcare professional network access.
• Medical Professional Relations Inc.minorOthersGroup company providing professional relations services within the MIHD pharmaceutical marketing group.
• HEARTS, Inc.minorOthersGroup company within the MIHD pharmaceutical marketing group.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Interscience